ALS20-101 Lentiviral Gene Therapy(The Children'S Hospital Of Philadelphia)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameALS20-101 Lentiviral Gene Therapy(The Children'S Hospital Of Philadelphia)
Drug Alias NameGene Therapy Employing Lentiviral Vector ALS20-transduced Hematopoietic Progenitor Cells Therapy(The Children'S Hospital Of Philadelphia)ALS20ALS-20
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionGene transference
TargetsNot applicable
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildrens Hospital of Philadelphia
China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of Philadelphia
Inactive CompaniesN/A
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A